Tag: Ranibizumab
Lupin receives European Commission approval for Biosimilar Ranibizumab
Lupin’s biosimilar ranibizumab will be commercialized by Sandoz across the European Union (excluding Germany)
Lupin receives positive CHMP opinion for Biosimilar Ranibizumab
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A)
Lupin and SteinCares enter into license & supply agreement for Ranibizumab...
SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same
Lupin completes Phase 3 trials for Lucentis Biosimilar
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Lupin and Amman Pharma sign exclusive licensing & supply agreement for...
Both Lupin and Amman Pharma are united in their mission to provide innovative, high-quality healthcare solutions to patients in the MENA region